# GTA-Glyceryltriacetate for Canavan Disease

> **NCT00278707** · PHASE1 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 5 (—)

## Conditions studied

- Infantile Canavan Disease
- Deficiency Disease, Aspartoacylase

## Interventions

- **DRUG:** GTA: Glyceryltriacetate

## Key facts

- **NCT ID:** NCT00278707
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 5 (—)
- **Last updated:** 2006-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278707, "GTA-Glyceryltriacetate for Canavan Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00278707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*